摘要
目的 探讨美托洛尔与伊伐布雷定对老年患者新型冠状病毒感染后直立性心动过速综合征(POTS)疗效的差异。方法 纳入2022年12月1日至2023年1月31日在首都医科大学附属北京朝阳医院心内科就诊并诊断为POTS的患者110例,按治疗药物不同分为美托洛尔组62例和伊伐布雷定组48例。比较2组治疗第28天门诊复诊静息心率、直立10 min心率、症状消失率、住院治疗率及病死率。结果 2组第28天门诊复诊静息心率、直立10 min心率均低于初诊(P<0.01);美托洛尔组与伊伐布雷定组第28天门诊复诊静息心率、直立10 min心率比较无显著差异[(71.0±7.0)次/min vs(72.1±7.0)次/min,P=0.401;(76.5±7.2)次/min vs(77.4±7.6)次/min,P=0.573]。美托洛尔组与伊伐布雷定组症状消失率、住院治疗率、病死率比较无显著差异(88.7%vs 89.6%,3.2%vs 2.1%,0%vs 0%,P>0.05)。结论 美托洛尔和伊伐布雷定均可有效治疗老年患者新型冠状病毒感染后POTS。
Objective To explore the difference in efficacy of metoprolol versus ivabradine in the treatment of postural orthostatic tachycardia syndrome(POTS)in the elderly after COVID-19 infection.Methods A total of 110patients diagnosed with POTS at our department from Decem-ber 1,2022to January 31,2023were included.According to their drug regimen,they were divided into metoprolol group(62patients)and ivabradine group(48patients).On the 28th day of out-patient follow-up,the resting heart rate,heart rate of 10min of standing,symptom disappearance rate,hospitalization rate,and mortality rate were compared between the two groups.Results On the 28th day of treatment,the resting heart rate and postural heart rate for 10min were decreased in both groups when compared with the levels at initial diagnosis(P<0.01).And there were no significant differences in the two types of heart rate between the two groups on the 28th day(71.0±7.0 vs 72.1±7.0,P=0.401;76.5±7.2 vs 77.4±7.6,P=0.573).No obvious differences were observed between the two groups in symptom disappearance rate,hospitalization rate,or mortality rate(88.7%vs 89.6%,3.2%vs 2.1%,0%vs 0%,P>0.05).Conclusion Metoprolol and ivabradine can effectively treat POTS in the elderly patients after COVID-19infection.
作者
关晓楠
刘文婷
黄雯
马桂伶
胡玫
齐丹
宗敏
赵华
李飞鸥
张建军
Guan Xiaonan;Liu Wenting;Huang Wen;Ma Guiling;Hu Mei;Qi Dan;Zong Min;Zhao Hua;Li Fei'ou;Zhang Jianjun(Department of Cardiology,Beijing Chaoyang Hospital,Capital Medical University,Beijing100043,China)
出处
《中华老年心脑血管病杂志》
CAS
北大核心
2024年第3期280-283,共4页
Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
